Results from Preclinical Studies:

In vivo, BioACT Matrix promoted repair of large cortico-cancellous bone defects (10 mm diameter x 18 mm length) in the distal femur of mature sheep.

Histomorphometric and microCT analyses found that the % bone was significantly greater for BioACT Matrix (27.5+16.1%*, n=4) in comparison to the PCL only scaffold (PCL CTRL) (2.7+1.4%, n=4) and untreated defect (defect only) (4.5+3.9%, n=3) at 8 weeks (*p<0.05).

The % bone for BioACT Matrix at 8 weeks was comparable to autologous bone (27.0+8.0%) used in a similar defect model at 12 weeks, demonstrating the BioACT Matrix’s superior osteoconductive properties.

Robust Intellectual Property:

BioRegenics, Inc., holds exclusive licenses to the patents for BioAct Matrix from the New Jersey Institute of Technology. The intellectual property of this technology is protected by a portfolio of four issued patents, covering U.S., Germany and Japan, for composition and method of use, including incorporation of growth factors into BioACT Matrix. One additional patent application has been filed for the incorporation of small molecules.

Funding Awarded:

$525K from Walter H. Coulter Foundation

Since 1998, the Wallace H. Coulter Foundation has provided risk capital for innovative initiatives through grants. Its university-based translational research grant programs utilize best practices of industry to accelerate academic innovations to the marketplace for improving patient care.

$200K from University City Science Center QED Proof-of-Concept Round 10

The QED Proof-of-Concept program provides funding for academic researchers developing early-stage life science and healthcare technologies with high commercial potential. Since the program’s inception in 2009, QED has screened over 640 proposals from 22 participating academic and research institutions. Of the technologies screened, 138 projects have been accepted into the competitive program. Projects awarded funding by the QED program have raised over $22 million in follow-on funding.